REMINDER: Microbot Medical to Highlight FDA 510(k) Clearance of the LIBERTY Endovascular Robotic System at the H.C. Wainwright Annual Investor Conference
Microbot Medical (NASDAQ:MBOT) announced that CEO Harel Gadot will present at the H.C. Wainwright Annual Investor Conference, focusing on the company's recent FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System. The LIBERTY® System is notable as the first single-use, remotely operated robotic system designed for peripheral endovascular procedures.
The presentation is scheduled for September 9th at 9:00am ET and will be available via webcast through the company's website.
Microbot Medical (NASDAQ:MBOT) ha annunciato che l'amministratore delegato Harel Gadot presenterà alla H.C. Wainwright Annual Investor Conference, con un focus sulla recente approvazione FDA 510(k) del suo sistema robotico endovascolare LIBERTY®. Il sistema LIBERTY® è il primo sistema robotico monouso e teleoperato progettato per procedure endovascolari periferiche.
La presentazione è prevista per il 9 settembre alle 9:00 ET e sarà fruibile in webcast tramite il sito web dell'azienda.
Microbot Medical (NASDAQ:MBOT) anunció que el CEO Harel Gadot presentará en la H.C. Wainwright Annual Investor Conference, centrándose en la reciente autorización FDA 510(k) de su sistema robótico endovascular LIBERTY®. El sistema LIBERTY® destaca por ser el primer sistema robótico de un solo uso y operado de forma remota diseñado para procedimientos endovasculares periféricos.
La presentación está programada para el 9 de septiembre a las 9:00 a.m. ET y estará disponible por webcast a través del sitio web de la compañía.
Microbot Medical (NASDAQ:MBOT)는 CEO 하렐 가돗(Harel Gadot)이 H.C. Wainwright 연례 투자자 컨퍼런스에서 자사 LIBERTY® 혈관 로봇 시스템의 최근 FDA 510(k) 승인에 대해 발표할 예정이라고 발표했습니다. LIBERTY® 시스템은 말초 혈관 시술을 위해 설계된 최초의 일회용 원격 조작 로봇 시스템으로 주목받고 있습니다.
발표는 현지 시각 9월 9일 오전 9:00 ET에 예정되어 있으며 회사 웹사이트를 통해 웹캐스트로 시청할 수 있습니다.
Microbot Medical (NASDAQ:MBOT) a annoncé que le PDG Harel Gadot présentera lors de la H.C. Wainwright Annual Investor Conference, en mettant l'accent sur la récente autorisation FDA 510(k) de son système robotique endovasculaire LIBERTY®. Le système LIBERTY® est remarquable en tant que premier système robotique à usage unique, opéré à distance conçu pour les procédures endovasculaires périphériques.
La présentation est prévue le 9 septembre à 9h00 ET et sera accessible en webcast via le site web de la société.
Microbot Medical (NASDAQ:MBOT) gab bekannt, dass CEO Harel Gadot auf der H.C. Wainwright Annual Investor Conference präsentieren wird. Im Mittelpunkt steht die jüngste FDA-510(k)-Zulassung für das endovaskuläre Robotersystem LIBERTY®. Das LIBERTY®-System ist bemerkenswert als das erste Einweg‑Robotersystem, das ferngesteuert für periphere endovaskuläre Eingriffe entwickelt wurde.
Die Präsentation ist für den 9. September um 9:00 Uhr ET angesetzt und wird per Webcast über die Unternehmenswebsite verfügbar sein.
- None.
- None.
Live Presentation to be Webcast Today at 9am ET
HINGHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and manufacturer of the innovative LIBERTY® Endovascular Robotic System, today announced that Harel Gadot, CEO, President & Chairman, will highlight the recent FDA clearance of the LIBERTY® System, the first single-use, remotely operated robotic system for peripheral endovascular procedures, at the H.C. Wainwright Annual Investor Conference. The Company’s presentation will be delivered today, September 9th at 9:00am ET, and a live webcast may be accessed via the ‘Events’ section of the Company’s website at www.microbotmedical.com.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a breakthrough medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
Learn more at www.microbotmedical.com and connect on LinkedIn and X.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company’s need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Contacts:
IR@microbotmedical.com
Media@microbotmedical.com
FAQ
When is Microbot Medical (MBOT) presenting at the H.C. Wainwright Conference?
What is Microbot Medical's LIBERTY Endovascular Robotic System?
How can investors access Microbot Medical's H.C. Wainwright conference presentation?
What recent FDA clearance did Microbot Medical (MBOT) receive?
